Bio-Gene Technology (ASX:BGT) Operating Cash Flow per Share : A$-0.01 (TTM As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Bio-Gene Technology Operating Cash Flow per Share?

Bio-Gene Technology's operating cash flow per share for the six months ended in Dec. 2024 was A$-0.00. Bio-Gene Technology's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2024 was A$-0.01.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -4.90% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Bio-Gene Technology's Operating Cash Flow per Share or its related term are showing as below:

ASX:BGT' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -12.6 Med: 3.5 Max: 13.4
Current: -4.9

During the past 7 years, Bio-Gene Technology's highest 3-Year average Operating Cash Flow per Share Growth Rate was 13.40% per year. The lowest was -12.60% per year. And the median was 3.50% per year.

ASX:BGT's 3-Year OCF Growth Rate is ranked worse than
66.2% of 1213 companies
in the Biotechnology industry
Industry Median: 9.5 vs ASX:BGT: -4.90

Bio-Gene Technology Operating Cash Flow per Share Historical Data

The historical data trend for Bio-Gene Technology's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Gene Technology Operating Cash Flow per Share Chart

Bio-Gene Technology Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.01

-0.02

Bio-Gene Technology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Operating Cash Flow per Share	Get a 7-Day Free Trial										-0.01	-0.01	-0.01	-0.01	-

Competitive Comparison of Bio-Gene Technology's Operating Cash Flow per Share

For the Biotechnology subindustry, Bio-Gene Technology's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Gene Technology's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Gene Technology's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Bio-Gene Technology's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Bio-Gene Technology Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Bio-Gene Technology's Operating Cash Flow per Share for the fiscal year that ended in Jun. 2024 is calculated as

Operating Cash Flow per Share (A: Jun. 2024 )	=	Cash Flow from Operations (A: Jun. 2024 )	/	Shares Outstanding (Diluted Average) (A: Jun. 2024 )
	=	-2.754	/	185.818
	=	-0.01

Bio-Gene Technology's Operating Cash Flow per Share for the quarter that ended in Jun. 2024 is calculated as

Operating Cash Flow per Share (Q: Dec. 2024 )	=	Cash Flow from Operations (Q: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2024 )
	=	-0.872	/	200.654
	=	-0.00

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.01

Bio-Gene Technology Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Bio-Gene Technology's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Gene Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Gene Technology Ltd (ASX:BGT) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Collins Street, Level 6, Melbourne, VIC, AUS, 3000

Website

https://www.bio-gene.com.au

Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance. Its products are Flavocide and Qcide which include a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. The group's product has multiple applications across public health, crop protection, grain storage, and consumer use. It provides new options derived from nature to meet market demand for effective and safe pest management solutions.

Bio-Gene Technology Headlines

From GuruFocus

Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

By Business Wire Business Wire • 12-20-2021

BlackRock Floating Rate Income Trust (BGT) Maintains Monthly Dividend Payout

By GuruFocus News • 04-02-2025